Previous 10 | Next 10 |
iBio press release ( NYSE: IBIO ): FY Revenue of $2.4M (+1.3% Y/Y) misses by $0.15M . Net loss was $50.3 million, an increased loss of $27.1 million compared to 2021 due to increased R&D and administrative expenses incurred. iBio held cash, cash equivalents and...
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming ® Manufacturing System, today...
Plant-based drugs developer iBio ( NYSE: IBIO ) on Wednesday said it had acquired all assets of its partner, AI-drug discovery company RubrYc Therapeutics, for an upfront payment of $1M in its common stock. IBIO stock jumped 8.9% to $0.37 in morning trading. The ac...
– Positions Company for leadership in AI-powered drug discovery – – Expands iBio’s immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss transaction, the Company’s transf...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The first half of 2022 for the stock market was the worst since 1970. Consequently, investors are forced to re-evaluate their portfolios and discard risky assets. Therefore, the topic of which penny stocks to sell is highly...
iBio ( NYSE: IBIO ) on Tuesday announced an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease. The company said it recently completed its first manufacturing run of its proprietary nucleocapsid antigen under...
- Manufactured first batch of drug substance under cGMP conditions - - Analysis of challenge study data underway - BRYAN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generat...
Catalyst Biosciences is highly committed to its cash distribution plan to shareholders of up to $65 million in the near future, with only a $58 million market capitalization. If the proxy contest is cleared up between Catalyst and JDS1 and goes in favor of the executives of Catalyst, ...
iBio ( NYSE: IBIO ) shareholders have approved the company's proposal to provide for a 1-for-25 share reverse stock split. Shares are up 7% in Wednesday morning trading. However, an SEC filing states that the split would only happen if the company board deems i...
3 Penny Stocks to Watch in July 2022 While investing in penny stocks can be challenging, it can be a great way to make money in the stock market. Because they are so volatile, investors need to be careful when choosing the best penny stocks to buy. And, if done correctly, penny stocks...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...